Rockefeller Capital Management L.P. Hutchmed (China) LTD Transaction History

Rockefeller Capital Management L.P.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$8.59 - $20.77 $2,963 - $7,165	-345 Reduced 94.78%	19 $0
Q1 2022 May 13, 2022	BUY	$15.52 - $35.65 $4,857 - $11,158	313 Added 613.73%	364 $6,000
Q2 2021 Aug 10, 2021	BUY	$23.7 - $39.27 $450 - $746	19 Added 59.38%	51 $2,000
Q4 2020 Feb 12, 2021	BUY	$27.51 - $34.36 $880 - $1,099	32 New	32 $1,000
Q2 2020 Aug 12, 2020	SELL	$17.65 - $28.05 $7,059 - $11,220	-400 Closed	0 $0
Q1 2020 May 12, 2020	SELL	$15.19 - $29.51 $774 - $1,505	-51 Reduced 11.31%	400 $7,000
Q4 2019 Feb 07, 2020	BUY	$17.17 - $25.95 $875 - $1,323	51 Added 12.75%	451 $11,000
Q1 2019 May 10, 2019	BUY	$21.27 - $30.58 $8,508 - $12,232	400 New	400 $12,000

6.88M

6.2K

1.1K

Ticker HCM
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 172,955,008
Market Cap $2.47B
Description
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...

Get notified when there are updates to the investment portfolio of Rockefeller Capital Management L.P., based on Form 13F filings with the SEC.

Stay updated on Rockefeller Capital Management L.P. with notifications on news.